Relation of ischemic cardioª²cerebro vascular diseases with platelet microparticle and expression of functional membrane protein

    SU Bing, WANG Qian, SUN Deª²Hua, ZENG Fangª²Yin, LIU Fei, Zhang Mengª²Yu, QI Tao

    Department of Clinical Laborary, Nanfang Hospital, South Medical University, Guangzhou 510515, China

    ¡¾Abstract¡¿ AIM: To detect platelet microparticle (PMP), glycoprotein IIb/IIIa (PACª²1) and Pª²selection (CD62P) using whole blood flow cytometry (WBª²FCM) in whole blood before and after the treatment in patients with ischemic cardiovascular and cerebrovascular diseases and the activation ratio of PACª²1 and CD62P, and to explore the role of PMPs, PACª²1 and CD62P in the pathogenesis of thrombotic cardiovascular and cerebrovascular diseases as well as the clinical significance of detecting PMP and activation ratio of PACª²1 and CD62P in whole blood in the prediction of illness state and in the prognostic evaluation. METHODS: The quantity of PMP and activation ratio of CD62P and GPIIb/IIIa were measured before and after the treatment of patient group and control group using flow cytometry. RESULTS: ¢Ù Control group PMP: (65.5¡À9.8)/104Plt, CD62P: (3.2¡À0.8)%, PACª²1: (7.0¡À1.0)%; PMP:(64.3¡À8.3)/104Plt, PACª²1:(6.8¡À0.7)%, CD62P: (3.0¡À0.7)%, PMP:(64.3¡À8.2)/104Plt, PACª²1:(6.8¡À0.7)%, CD62P:(3.0¡À0.7)%; ¢Ú Before treatment of patient group(with thrombotic cardiovascular disease): PMP:(209.2¡À21.9)/104Plt, CD62P: (54.7¡À7.8)%, PACª²1:(87.4¡À7.1)%; After treatment: PMP:(117.9¡À11.9)/104Plt, CD62P:(25.2¡À6.3)%, PACª²1:(46.2¡À5.1)%; They were significantly higher than those in control group(P<0.01), and significantly lower after treatment of patient group than before treatment(P<0.01). ¢Û Before treatment of patient group(with thrombotic cerebrovascular disease): PMP:(217.3¡À36.6)/104Plt, CD62P:(52.8¡À9.3)%, PACª²1:(79.9¡À6.8)%; After treatment: PMP:(134.2¡À12.9)/104Plt, CD62P:(24.3¡À6.1)%, PACª²1:(42.2¡À5.1)%; They were significantly higher than those in control group(P<0.01), and significantly lower after treatment of patient group than before treatment(P<0.01). CONCLUSION: The levels of PMP, PACª²1 and CD62P can be taken as the specificity indices for the evaluation of therapeutic efficacy, prognostic judgement and clinical diagnosis. And it provides theoretical basis for the longª²term medication therapies for cardioª²cerebrovascular diseases. ......